Teva keeps the faith after another rebuke for Copaxone’s heir

Damian Garde

's $ 4-billion-a-year multiple sclerosis treatment Copaxone is slated to lose patent protection next year, and the Israeli drugmaker is struggling to move the needle on its planned replacement, enduring rejection from European reviewers.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS